Covid-19: India To Have A Dedicated Vaccine Portal

The proposed portal will have sections like like-COVID-19 vaccine, India's initiative, International Symposium and FAQ.

Soon, India will have a dedicated vaccine portal which will act as repository for all information related to vaccine development.

The portal is being developed by the country’s top medical body ICMR, and is expected to be live by the next week.

Initially, the portal will show all the information related to vaccine development for Covid-19. Gradually, this portal will show information related to all the vaccines used to prevent various diseases.

Presently, there is no one place where you can go to access information related to available and future vaccines in India. Information are all over the place. Talking to a news agency, Dr Samiran Panda, Scientist G & head of Epidemiology and Communicable Diseases (ECD), Division at ICMR, said that the proposed portal will be strengthened with data available for all the vaccines in the months ahead.

“The Central government along with the ICMR is making all best efforts to combat coronavirus pandemic. Wearing masks, hand-hygiene and social distancing are preventive measures but at the same time vaccine development is another important aspect which will be updated on the ICMR vaccine portal,” said Dr Panda.

The proposed portal will have sections like like-COVID-19 vaccine, India’s initiative, International Symposium and FAQ. There is a plan to present FAQs in regional languages so that the general public can access this information.

Currently, there are three Covid vaccine candidates are in India, and all these candidates are in different phase of the clinical trials.

‘Bharat Biotech Vaccine’ is being developed in collaboration with the ICMR. The second oneis being developed by Zydus Cadila.

While the vaccine developed by the Bharat Biotech is an inactivated virus vaccine, Zydus Cadilla’s vaccine will be a ‘DNA vaccine.

Drugs Controller General of India (DCGI) gave its approval to Serum Institute of India (SII) to develop a ‘Recombinant Oxford University vaccine’.

Facebook Comments